Research Atlas · source screening

Dalbavancin

An attributable first-pass index of PubMed records whose titles name this governed identity. Records are sorted by publication date, not by evidence strength. Inclusion does not establish efficacy, safety, or a clinical indication.

Title-search results

527

Shown with stable PMIDs

25

Search recorded

2026-09-26

Source: NCBI PubMed / MEDLINE · exact query: "Dalbavancin"[Title] · up to 25 recent title matches per identity. Each result links to its PubMed record.

1. Production improvement of dalbavancin precursor A40926B0 in Nonomuraea gerenzanensis through strain reconstruction and fermentation optimization.

   Synth Syst Biotechnol · 2027 Mar · PMID 42598089 · DOI 10.1016/j.synbio.2026.07.003

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

2. Clinical use of dalbavancin in Canada: the clear study final results.

   Expert Rev Anti Infect Ther · 2026 Sep 25 · PMID 42788820 · DOI 10.1080/14787210.2026.2740112

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

3. Economic Outcomes of Dalbavancin versus Standard Therapy in Staphylococcus aureus Bacteremia in the DOTS Randomized Clinical Trial.

   Clin Infect Dis · 2026 Sep 17 · PMID 42752824 · DOI 10.1093/cid/ciag567

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

4. Corrigendum to "Comparison of dalbavancin with standard of care in the management of infective endocarditis: efficacy, safety, and cost analysis" [International Journal of Infectious Diseases, Volume 138 (January 2024), Pages 41-45].

   Int J Infect Dis · 2026 Sep · PMID 42430947 · DOI 10.1016/j.ijid.2026.108901

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

5. Emergence of dalbavancin non-susceptible methicillin-resistant Staphylococcus epidermidis (MRSE) in a patient treated with dalbavancin prolonged therapy: Case report, therapeutic drug monitoring and genomic characterization.

   Int J Antimicrob Agents · 2026 Sep · PMID 42250705 · DOI 10.1016/j.ijantimicag.2026.107877

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

6. Genome sequence of a methicillin-resistant Staphylococcus epidermidis (MRSE) resistant to dalbavancin and teicoplanin isolated in Italy, 2023.

   J Glob Antimicrob Resist · 2026 Sep · PMID 42167682 · DOI 10.1016/j.jgar.2026.05.006

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

7. Clinical outcomes of dalbavancin versus standard therapy for non-severe skin and soft-tissue infections as well as bone and joint infections: a retrospective observational study.

   JAC Antimicrob Resist · 2026 Aug · PMID 42621246 · DOI 10.1093/jacamr/dlag175

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

8. Expanding the Role of Dalbavancin in Children: A Case Series and Systematic Review.

   Pediatr Infect Dis J · 2026 Aug 10 · PMID 42572145 · DOI 10.1097/INF.0000000000005362

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

9. Population pharmacokinetics of dalbavancin: external validation, model averaging, and implications for precision dosing in prolonged therapy.

   Antimicrob Agents Chemother · 2026 Aug 5 · PMID 42363831 · DOI 10.1128/aac.00665-26

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

10. Synergy between orally bioavailable antibiotics and dalbavancin against MRSA.

    J Antimicrob Chemother · 2026 Aug 4 · PMID 42572117 · DOI 10.1093/jac/dkag264

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

11. A real-world implementation study of a TDM-guided dalbavancin model for bone and joint infections (101 Dalbatians).

    JAC Antimicrob Resist · 2026 Aug · PMID 42405345 · DOI 10.1093/jacamr/dlag127

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

12. Projected health-service cost impact of dalbavancin consolidation therapy for Staphylococcus aureus bacteraemia in an Australian public health system.

    Intern Med J · 2026 Jul 30 · PMID 42531603 · DOI 10.1111/imj.70572

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

13. Reply to the comment on: "Dalbavancin for infective endocarditis: a systematic review of effectiveness, safety, and dosing".

    Eur J Clin Microbiol Infect Dis · 2026 Jul 10 · PMID 42429893 · DOI 10.1007/s10096-026-05597-z

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

14. Real-world use of Dalbavancin for vascular graft and Endograft infections.

    Infect Dis Now · 2026 Jul · PMID 42331326 · DOI 10.1016/j.idnow.2026.105313

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

15. Relationship Between Patient's Body Mass Index and Dalbavancin's Effectiveness in the Treatment of Invasive Gram-Positive Infections.

    Ann Pharmacother · 2026 Jul · PMID 41321256 · DOI 10.1177/10600280251389823

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

16. Real-World Effectiveness of Dalbavancin in Osteomyelitis Without Implantable Devices: A Retrospective Monocentric Study.

    Antibiotics (Basel) · 2026 Jun 26 · PMID 42505603 · DOI 10.3390/antibiotics15070640

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

17. Optimizing dalbavancin dosing for complicated methicillin-resistant Staphylococcus aureus infections: a multicentre population pharmacokinetic study.

    Clin Microbiol Infect · 2026 Jun 8 · PMID 42264180 · DOI 10.1016/j.cmi.2026.05.049

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

18. Comment on: "Dalbavancin for infective endocarditis: a systematic review of effectiveness, safety, and dosing".

    Eur J Clin Microbiol Infect Dis · 2026 Jun 8 · PMID 42257986 · DOI 10.1007/s10096-026-05563-9

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

19. Emerging resistance in staphylococci following long-term dalbavancin treatment for prosthetic joint infections.

    J Antimicrob Chemother · 2026 Jun 3 · PMID 42372046 · DOI 10.1093/jac/dkag218

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

20. Practical vs Recent Clinical Trial Use Of Dalbavancin.

    JAMA Netw Open · 2026 Jun 1 · PMID 42234430 · DOI 10.1001/jamanetworkopen.2026.16508

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

21. Evaluating Dalbavancin Suppression Therapy in Patients at High Risk for Recurrent Infections.

    Ann Pharmacother · 2026 May 26 · PMID 42198790 · DOI 10.1177/10600280261445133

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

22. Dalbavancin in the Real-World Management of Gram-Positive Infections: A Systematic Review of Randomized and Observational Studies.

    Microorganisms · 2026 May 9 · PMID 42197456 · DOI 10.3390/microorganisms14051071

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

23. Efficacy and safety of dalbavancin as suppressive therapy in chronic implant-associated infections.

    Infect Dis Now · 2026 May · PMID 41941928 · DOI 10.1016/j.idnow.2026.105268

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

24. Real-world effectiveness of dalbavancin for invasive gram-positive bacterial infections.

    Am J Health Syst Pharm · 2026 Apr 7 · PMID 41172330 · DOI 10.1093/ajhp/zxaf301

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

25. Pharmacokinetics of Dalbavancin in Complicated Staphylococcus aureus Bacteremia: A Secondary Analysis of the DOTS Randomized Clinical Trial.

    JAMA Netw Open · 2026 Apr 1 · PMID 41999282 · DOI 10.1001/jamanetworkopen.2026.11652

    Source metadata only · evidence grade unassigned · scientific conclusions pending review